Weekly Research Analysts’ Ratings Updates for Praxis Precision Medicines (PRAX)

Praxis Precision Medicines (NASDAQ: PRAX) recently received a number of ratings updates from brokerages and research firms:

• 7/13/2026 – Praxis Precision Medicines had its “overweight” rating reaffirmed by Piper Sandler.
• 7/13/2026 – Praxis Precision Medicines is now covered by The Goldman Sachs Group, Inc.. They set a “buy” rating and a $447.00 price target on the stock.
• 7/13/2026 – Praxis Precision Medicines is now covered by The Goldman Sachs Group, Inc.. They set a “buy” rating and a $447.00 price target on the stock.
• 6/29/2026 – Praxis Precision Medicines had its price target raised by Needham & Company LLC from $537.00 to $575.00. They now have a “buy” rating on the stock.
• 6/17/2026 – Praxis Precision Medicines is now covered by Royal Bank Of Canada. They set an “outperform” rating and a $449.00 price target on the stock.
• 6/17/2026 – Praxis Precision Medicines was upgraded by Royal Bank Of Canada to “moderate buy”.
• 6/2/2026 – Praxis Precision Medicines had its “buy” rating reaffirmed by TD Cowen.
• 6/2/2026 – Praxis Precision Medicines was given a new $616.00 price target by Truist Financial Corporation. They now have a “buy” rating on the stock.
• 6/2/2026 – Praxis Precision Medicines had its “outperform” rating reaffirmed by Oppenheimer Holdings, Inc.. They now have a $650.00 price target on the stock, down from $750.00.
• 6/2/2026 – Praxis Precision Medicines had its “buy” rating reaffirmed by BTIG Research. They now have a $810.00 price target on the stock, down from $843.00.
• 6/2/2026 – Praxis Precision Medicines had its “buy” rating reaffirmed by Deutsche Bank Aktiengesellschaft. They now have a $374.00 price target on the stock, down from $420.00.
• 6/2/2026 – Praxis Precision Medicines had its price target lowered by Wedbush from $166.00 to $162.00. They now have an “underperform” rating on the stock.
• 6/2/2026 – Praxis Precision Medicines had its price target lowered by Robert W. Baird from $433.00 to $400.00. They now have an “outperform” rating on the stock.
• 6/2/2026 – Praxis Precision Medicines had its price target lowered by HC Wainwright from $1,245.00 to $1,201.00. They now have a “buy” rating on the stock.
• 5/27/2026 – Praxis Precision Medicines had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 5/26/2026 – Praxis Precision Medicines had its “buy” rating reaffirmed by HC Wainwright. They now have a $1,245.00 price target on the stock.
• 5/20/2026 – Praxis Precision Medicines had its “buy” rating reaffirmed by BTIG Research. They now have a $843.00 price target on the stock.

Insider Buying and Selling at Praxis Precision Medicines

In other news, Director Jill Desimone sold 11,600 shares of Praxis Precision Medicines stock in a transaction that occurred on Wednesday, June 24th. The stock was sold at an average price of $311.32, for a total transaction of $3,611,312.00. Following the sale, the director owned 2,337 shares of the company’s stock, valued at approximately $727,554.84. The trade was a 83.23% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 3.00% of the company’s stock.

Praxis Precision Medicines is a clinical-stage biopharmaceutical company focused on discovering and developing precision therapies for disorders driven by neuronal excitability. The company applies translational neuroscience and genetic insights to design small molecule drugs that target specific ion channels and receptor subtypes implicated in neurological and psychiatric conditions. Its research aims to address unmet needs in rare epilepsies, essential tremor, treatment-resistant depression and other central nervous system (CNS) disorders.

The company’s pipeline includes several lead candidates at various stages of development.